Full-Time

Associate Director

Quality Control, Reference Standards

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$190k - $197kAnnually

Senior

San Carlos, CA, USA

This position is hybrid.

Category
Healthcare Administration & Support
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Supply Chain Management
Inventory Management
Requirements
  • Ph.D. with 8+ years of AD/QC experience or MS/BS with 12+ years of AD/QC experience, including 5+ years in reference standard management within the vaccine, biotech, or pharma industry.
  • Strong understanding of relevant cGMP, FDA, EU, and ICH regulatory guidance associated with release and characterization assays.
  • Strong knowledge of regulatory requirements and quality standards in the pharmaceutical industry.
  • Broad experience with biochemistry, immunoassay, biological, and microbiological assays.
  • Strong biostatistics background for evaluating comparability and qualification of reference standards. Experience with LIMS, analytical statistics, and statistical software (e.g., JMP).
  • Ability to work globally with external suppliers (CDMOs/ CROs/ CTLs) in a team-oriented environment under dynamic conditions.
  • Ability to work in a fast-paced team environment and to consistently meet aggressive timelines while prioritizing tasks for multiple projects.
  • Self-starter with strong problem-solving skills and excellent interpersonal communication abilities.
  • Strong written and verbal communication skills, and efficient in communicating with inter-disciplinary and cross-functional teams.
  • Good organization and planning skills.
Responsibilities
  • Act as the main point of contact in the Vaxcyte QC organization and responsible for the developing and implementation of policies, procedures, and strategies for Vaxcyte's global reference standard and critical reagent management systems to support continuous testing and the release of clinical and commercial products.
  • Lead the development of global business practices, policies, and standards for reference standards and critical reagents, including qualification/requalification, resupply, and inventory management.
  • Author or oversee the authoring of technical protocols, qualification reports, requalification reports, and expiry extension reports for reference standards and critical reagents.
  • Oversee the monitoring of manufacturing schedules, request materials for reference samples and critical reagents, and coordinate support activities.
  • Establish and maintain the trending program for reference standards and critical reagents in collaboration with internal teams and external partners. Responsible for reviewing and managing OOS/OOT and deviations and developing strategies and decisions in risk mitigation around reference standards and critical reagents.
  • Develop, manage, and optimize processes and projections for critical reagent supply planning, including inventory management, logistics, and space planning.
  • Collaborate with internal teams (Process Development, Quality, Regulatory, Supply Chain, and Commercial) and external partners (CDMOs/ CROs/ CTLs) to continuously supply qualified reference standards and critical reagents.
  • Oversee or coordinate the generation of critical reagents with other support areas and external contractors as needed.
  • Apply technical and compliance expertise in reviewing test methods and in-process/release documentation, providing technical and compliance feedback to internal and external stakeholders.
  • Author and review internal Certificates of Analysis and SOPs related to Quality Control policies and procedures.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

19%

1 year growth

61%

2 year growth

129%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?